Virometix: Virometix : Announces Initiation of Phase 1 Clinical Trial With Its V-306 Vaccine Candidate

(marketscreener.com) Virometix, a privately held Swiss biotechnology company developing a new generation of vaccines and immunotherapeutic drugs for the prevention and treatment of infectious and oncology diseases, is pleased to announce that the Belgian health authority, FAMHP, has approved the company's clinical trial application for the first-in-human phase...https://www.marketscreener.com/news/Virometix-Announces-Initiation-of-Phase-1-Clinical-Trial-With-Its-V-306-Vaccine-Candidate--30147785/?utm_medium=RSS&utm_content=20200312